| Overview |
| bs-1830R |
| IL-16 Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human IL-16 |
| 25-125/1332 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 3603 |
| Cytoplasm, Nucleus, Secreted |
| Interleukin-16; HGNC:5980; HsT19289; Interleukin 16 precursor; LCF; Lymphocyte Chemotactic Factor; IL16; Lymphocyte chemoattractant factor; PrIL16; IL16_HUMAN. |
| IL16 is a proinflammatory cytokine that is chemotactic for CD4+ T lymphocytes, monocytes, and eosinophils. IL16 is synthesized as a precursor molecule (pro IL16) of approximately 68 kDa and 631 amino acid residues lacking a signal peptide. The sequence and structure of IL16 is conserved across species. In addition to inducing chemotaxis, IL16 upregulates the IL2 receptor and upregulates HLADR expression. It also inhibits T cell receptor (TCR)/CD3 dependent activation, and suppresses HIV1 replication in vitro. Sources of IL16 include epithelial cells, mast cells, T lymphocytes (CD4+ and CD8+), macrophages, synovial fibroblasts, and eosinophils. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz